130 related articles for article (PubMed ID: 17721501)
21. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema.
Zein WM; Noureddin BN; Jurdi FA; Schakal A; Bashshur ZF
Retina; 2006 Feb; 26(2):137-42. PubMed ID: 16467667
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
Jonas JB
Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
[TBL] [Abstract][Full Text] [Related]
23. Frequency and management of raised intraocular pressure following intravitreal triamcinolone acetonide.
Mahar PS; Memon AS
J Coll Physicians Surg Pak; 2012 Nov; 22(11):699-702. PubMed ID: 23146849
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal triamcinolone acetonide for the management of papillophlebitis and associated macular edema.
Chang YC; Wu WC
Int Ophthalmol; 2008 Aug; 28(4):291-6. PubMed ID: 17701380
[TBL] [Abstract][Full Text] [Related]
25. Regression of optic nerve head neovascularization in proliferative diabetic retinopathy after intravitreal triamcinolone. Regression of diabetic optic disc neovascularization after intravitreal triamcinolone.
Karacorlu M; Ozdemir H; Karacorlu S; Alacali N
Int Ophthalmol; 2004 Mar; 25(2):113-6. PubMed ID: 15290890
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal and posterior subtenon triamcinolone acetonide in idiopathic bilateral uveitic macular oedema.
Choudhry S; Ghosh S
Clin Exp Ophthalmol; 2007 Nov; 35(8):713-8. PubMed ID: 17997773
[TBL] [Abstract][Full Text] [Related]
27. Cataract surgery combined with intravitreal injection of triamcinolone acetonide.
Jonas JB; Kreissig I; Budde WM; Degenring RF
Eur J Ophthalmol; 2005; 15(3):329-35. PubMed ID: 15945000
[TBL] [Abstract][Full Text] [Related]
28. Toxic vitreitis outbreak after intravitreal injection.
Ness T; Feltgen N; Agostini H; Böhringer D; Lubrich B
Retina; 2010 Feb; 30(2):332-8. PubMed ID: 20175274
[TBL] [Abstract][Full Text] [Related]
29. Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration.
Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B
Ophthalmic Res; 2006; 38(6):324-8. PubMed ID: 17047404
[TBL] [Abstract][Full Text] [Related]
30. Safety profile of intravitreal triamcinolone acetonide.
Baath J; Ells AL; Crichton A; Kherani A; Williams RG
J Ocul Pharmacol Ther; 2007 Jun; 23(3):304-10. PubMed ID: 17593015
[TBL] [Abstract][Full Text] [Related]
31. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor.
de la Sayette V; Bertran F; Honnorat J; Schaeffer S; Iglesias S; Defer G
Arch Neurol; 1998 Mar; 55(3):405-8. PubMed ID: 9520015
[TBL] [Abstract][Full Text] [Related]
32. [Intravitreal injection of triamcinolone acetonide for the treatment of macular edema].
Ladjimi A; Zeghidi H; Ben Yahia S; Zaouali S; Jenzri S; Messaoud R; Attia S; Khairallah M
J Fr Ophtalmol; 2005 Sep; 28(7):749-57. PubMed ID: 16208226
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide].
Jonas JB; Kreissig I; Degenring RF
Klin Monbl Augenheilkd; 2003 Jun; 220(6):384-90. PubMed ID: 12830391
[TBL] [Abstract][Full Text] [Related]
34. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
[TBL] [Abstract][Full Text] [Related]
35. Collapsin response mediator protein 5-associated optic neuropathy: clinical characteristics, radiologic clues, and outcomes.
Yan R; Mao Y; Zeng H; Liu Q; Jiang H; Peng J; Yang Q; Cui S; Liu L; Guo Y; Wang J
Front Neurol; 2023; 14():1163615. PubMed ID: 37448746
[TBL] [Abstract][Full Text] [Related]
36. Vision Preservation in Eyes of Polypoidal Choroidal Vasculopathy with Low-Dose Intravitreal Triamcinolone Acetonide.
Liang IC; Lin YR; Chien HW; Liu KR
J Ocul Pharmacol Ther; 2017; 33(1):42-49. PubMed ID: 27991837
[TBL] [Abstract][Full Text] [Related]
37. Acute endophthalmitis following intravitreal triamcinolone acetonide injection.
Moshfeghi DM; Kaiser PK; Scott IU; Sears JE; Benz M; Sinesterra JP; Kaiser RS; Bakri SJ; Maturi RK; Belmont J; Beer PM; Murray TG; Quiroz-Mercado H; Mieler WF
Am J Ophthalmol; 2003 Nov; 136(5):791-6. PubMed ID: 14597028
[TBL] [Abstract][Full Text] [Related]
38. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema.
Gillies MC; Simpson JM; Gaston C; Hunt G; Ali H; Zhu M; Sutter F
Ophthalmology; 2009 Nov; 116(11):2182-7. PubMed ID: 19796823
[TBL] [Abstract][Full Text] [Related]
39. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases.
Dubey D; Lennon VA; Gadoth A; Pittock SJ; Flanagan EP; Schmeling JE; McKeon A; Klein CJ
Neurology; 2018 Jan; 90(2):e103-e110. PubMed ID: 29222126
[TBL] [Abstract][Full Text] [Related]
40. High-titer collapsin response-mediating protein-associated (CRMP-5) paraneoplastic optic neuropathy and Vitritis as the only clinical manifestations in a patient with small cell lung carcinoma.
Margolin E; Flint A; Trobe JD
J Neuroophthalmol; 2008 Mar; 28(1):17-22. PubMed ID: 18347453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
